Chiesi
Chiesi is a privately held, family-owned global pharmaceutical group founded in 1935 that develops, manufactures, and commercializes prescription therapies across respiratory health, rare diseases, and specialty care (neonatology and transplantation) across 31 global affiliates and 7 R&D centers.
- Company typePrivate
- Founded1935
- HeadquartersManchester, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Chiesi firmographics
Firmographics- Name
- Chiesi
- Legal name
- Chiesi Limited
- Website
- https://chiesi.uk.com
- Company type
- Private
- Founded year
- 1935
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Chiesi is a privately held, family-owned global pharmaceutical group founded in 1935 that develops, manufactures, and commercializes prescription therapies across respiratory health, rare diseases, and specialty care (neonatology and transplantation) across 31 global affiliates and 7 R&D centers.
- Ownership category
- akta.pro rank
Chiesi industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
- akta.pro secondary industries
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)
Keywords
Where Chiesi is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Offices8 records
Markets served
Chiesi business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Chiesi generates revenue through development, manufacturing, and sale of prescription pharmaceutical products in respiratory health, rare diseases, and specialty care including neonatology and organ transplantation. Products are sold directly to healthcare systems, hospitals, pharmacies, and through NHS procurement.
- Rare Disease Portfolio Revenue: Revenue from rare disease treatments including Elfabrio ($49 million in 2025 sales), EKTERLY/sebetralstat ($49.1 million in 2025 following US launch), and lomitapide. Strategic goal to reach €6 billion in revenue by 2030.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Prescription pharmaceutical products - pricing determined through NHS and regulatory negotiations |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Chiesi product offering
Product offeringCore offering
Chiesi develops, manufactures, and commercializes prescription pharmaceutical products across three core therapeutic franchises: Air (respiratory health including asthma and COPD treatments delivered via pMDIs, DPIs, and nebulizers), Rare (therapies for rare and ultra-rare diseases including Fabry disease, HoFH, hereditary angioedema, lipodystrophy, cystinosis, and LHON), and Care (specialty products for neonatology and organ transplantation). The company also operates digital health initiatives including AI-powered vocal biomarker pilots and the Carbon Minimal Inhaler program targeting 90% carbon footprint reduction in respiratory treatments.
Product overview
Chiesi is a research-oriented international biopharmaceutical group with a diversified portfolio organized around three core disease areas: Air (respiratory health including asthma and COPD), Rare (rare and ultra-rare diseases), and Care (specialty care including neonatology and organ transplantation). The company operates both a core pharmaceutical portfolio and a dedicated Chiesi Global Rare Diseases business unit. The respiratory portfolio includes inhaled therapies delivered via multiple device formats: pMDI inhalers (Clenil Modulite, Fostair pMDI, Trimbow pMDI), dry powder inhalers (Fostair NEXThaler, Trimbow NEXThaler, Atimos Modulite), and nebulized antibiotics (Bramitob, Quinsair). The rare disease portfolio spans enzyme replacement therapies (Elfabrio for Fabry disease, Lamzede for alpha-mannosidosis), oral therapies (LOJUXTA for HoFH, Myalepta for lipodystrophy, Procysbi for cystinosis, Raxone for LHON), and acquired products (EKTERLY for hereditary angioedema). Specialty care includes neonatal products (Curosurf surfactant, Peyona caffeine), transplant immunosuppression (Envarsus tacrolimus), and supporting therapies across cardiovascular, hematology, and dermatology. Chiesi also operates digital health initiatives including the Carbon Minimal Inhaler program targeting 90% carbon footprint reduction, Salesforce-based commercial operations platforms, and AI-powered diagnostic technologies.
Differentiator
Problem solved
Functional benefit
Brands
- Chiesi Global Rare Diseases: Business unit delivering innovative therapies and solutions for people living with rare diseases including Fabry disease, cystinosis, lipodystrophy, and hereditary angioedema.
Products and services
- Clenil Modulite Pressurized metered dose inhaler (pMDI) containing beclometasone in 50mcg, 100mcg, 200mcg, and 250mcg strengths for asthma management. Chiesi's first carbon minimal inhaler candidate, with the HFA-152a formulation submitted to MHRA targeting up to 90% carbon footprint reduction.
- Fostair NEXThaler Dry powder inhaler combining beclometasone and formoterol in 100/6 and 200/6 dose strengths for asthma and COPD management.
- Fostair pMDI Pressurized metered dose inhaler combining beclometasone and formoterol in 100/6 and 200/6 dose strengths for respiratory disease treatment.
- Trimbow Triple combination therapy inhaler containing beclometasone, formoterol, and glycopyrronium available in multiple strengths and delivery formats (NEXThaler DPI and pMDI) for COPD management.
- Atimos Modulite Breath-actuated breath-coordinated modulit inhaler containing formoterol as a long-acting bronchodilator for asthma and COPD.
- Elfabrio (pegunigalsidase alfa) PEGylated enzyme replacement therapy for adult patients with Fabry disease. Plant cell culture-expressed recombinant alpha-galactosidase A enzyme with stabilized pharmacokinetics. Approved with standard 1mg/kg every-two-weeks dosing and additional 2mg/kg every-four-weeks regimen for ERT-stable patients, reducing infusion frequency from 26 to 13 annually.
- LOJUXTA (lomitapide) Microsomal triglyceride transfer protein inhibitor for Homozygous Familial Hypercholesterolaemia (HoFH). Originally approved for adults in 2013, with European Commission approval extended in June 2026 to include children 5 years and older.
- Myalepta (metreleptin) Recombinant human leptin analog for treatment of lipodystrophy. Chiesi Global Rare Diseases presented metreleptin research at ENDO 2026 across generalized and partial lipodystrophy, including combination therapy with GLP-1 receptor agonists.
- EKTERLY (sebetralstat) First and only oral, on-demand plasma kallikrein inhibitor for acute hereditary angioedema (HAE) attacks in patients 12 years and older. Acquired through Chiesi's $1.9 billion acquisition of KalVista Pharmaceuticals in June 2026. Approved in US, UK, EU, Japan, Australia, Switzerland, and Singapore. Generated $49 million in 2025 sales.
- Lamzede (velmanase alfa) Recombinant human alpha-mannosidase enzyme replacement therapy for alpha-mannosidosis, a rare lysosomal storage disorder.
- Procysbi (mercaptamine bitartrate) Delayed-release cysteamine bitartrate formulation for nephropathic cystinosis, reducing cystine accumulation in lysosomes.
- Raxone (idebenone) Synthetic short-chain coenzyme Q10 analog for Leber hereditary optic neuropathy (LHON). Received Complete Response Letter from FDA regarding New Drug Application.
- Curosurf (poractant alfa) Natural porcine pulmonary surfactant for treatment of respiratory distress syndrome in premature infants.
- Peyona (caffeine citrate) Caffeine citrate solution for primary apnea of premature newborns.
- Envarsus (tacrolimus monohydrate) Once-daily tacrolimus formulation for immunosuppression in kidney and liver transplant recipients.
- Bramitob (tobramycin) Inhaled tobramycin solution for Pseudomonas aeruginosa infection management in cystic fibrosis patients.
- Quinsair (levofloxacin) Inhaled levofloxacin for chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients.
- Ferriprox (deferiprone) Oral iron chelator for treatment of iron overload in thalassemia and other transfusion-dependent anemias.
- Filsuvez Gel Topical gel containing birch bark extract for junctional and dystrophic epidermolysis bullosa.
- Kengrexal (cangrelor) Intravenous P2Y12 platelet receptor antagonist for percutaneous coronary intervention.
- Cardioplen XL (felodipine) Extended-release calcium channel blocker for hypertension and angina in 2.5mg, 5mg, and 10mg strengths.
- Monomax XL (isosorbide mononitrate) Extended-release nitrate for prevention of angina pectoris.
- Clipper (budesonide) Budesonide formulation for inflammatory bowel conditions.
- Natecal D3 Calcium carbonate and cholecalciferol combination for calcium deficiency.
Quantifiable outcome
- Reduces carbon footprint of pMDIs by up to 90% compared to current HFA-134a inhalers
- +4 more outcomes
Companies that use Chiesi
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Chiesi technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Chiesi partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, major and minor.
- KalVista PharmaceuticalscoreAcquisition completed June 11, 2026 for $1.9 billion ($27 per share), making KalVista a wholly owned subsidiary. Acquisition adds EKTERLY (sebetralstat), first oral on-demand treatment for hereditary angioedema, to Chiesi's rare disease portfolio. Approximately 77.8% of shares tendered.
- SalesforcemajorChiesi selected Salesforce Agentforce Life Sciences platform to transform commercial operations, serving 3,300 users with unified data management through Data 360, AI-assisted field team support, and scalable commercial operations management. Partnership supports digital transformation amid geopolitical, regulatory, and supply chain pressures.
- NHS Englandcore£10 million Respiratory Transformation Partnership co-funded by NHS England and four pharmaceutical companies (AstraZeneca, Chiesi, GSK, Sanofi) to transform asthma and COPD care by shifting treatment from hospitals to local communities. Partnership uses data and digital tools to improve diagnosis and expand access to biologic medicines.
- BespakcoreExpanded partnership to increase pMDI manufacturing capacity at Bespak's Holmes Chapel site supporting Chiesi's Carbon Minimal Inhaler program. Partnership aims to reduce carbon footprint of pMDIs by up to 90% through transition to low GWP propellants. Reinforces both companies' sustainability commitments with Chiesi targeting Net Zero by 2035 and Bespak holding SBTi-validated decarbonization targets.
- Protalix BioTherapeuticscoreGlobal partnership for development and commercialization of pegunigalsidase alfa (Elfabrio) for Fabry disease. Chiesi received $25 million milestone payment following EC approval of E4W dosing regimen. Protalix manufactures using proprietary plant cell-based expression system ProCellEx.
- VoiceMedminorSix-month clinical pilot with Rome-based digital health startup to explore AI-powered vocal biomarker technology for early detection of COPD and chronic respiratory diseases via smartphone voice recordings.
- Gossamer BiocoreGlobal collaboration with Gossamer Bio for joint development of seralutinib in pulmonary arterial hypertension. Phase 3 PROSERA study completed with +13.3m improvement in Six-Minute Walk Distance at Week 24. Discussions with FDA ongoing for potential NDA submission.
- NHS Trusts (Multiple)coreMultiple collaborative working projects with NHS trusts including Manchester University NHS Foundation Trust (PIONEER post-transplant project), Hull University Teaching Hospitals (FRONTIER COPD diagnosis), Wirral Primary Care Collaborative (COMET), Health Innovation Manchester (MISSION), and Academic Health Science Network (NTEC neonatal project).
Scale indicators9 records
Recent moves7 records
Expansion highlights7 records
Chiesi competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks1 record
Key highlights6 records
Customer concentration
Chiesi social profiles
Digital presenceChiesi compliance and trust
Trust signalCompliance5 records
Chiesi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chiesi leadership team
Management profileNumber of profiles
Profiles12 records
Chiesi subsidiaries and ownership
Company hierarchySubsidiaries4 records
Chiesi funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chiesi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chiesi
What does Chiesi do?
Chiesi develops, manufactures, and commercializes prescription pharmaceutical products across three core therapeutic franchises: Air (respiratory health including asthma and COPD treatments delivered via pMDIs, DPIs, and nebulizers), Rare (therapies for rare and ultra-rare diseases including Fabry disease, HoFH, hereditary angioedema, lipodystrophy, cystinosis, and LHON), and Care (specialty products for neonatology and organ transplantation). The company also operates digital health initiatives including AI-powered vocal biomarker pilots and the Carbon Minimal Inhaler program targeting 90% carbon footprint reduction in respiratory treatments.
Is Chiesi a public or private company?
Chiesi is a private company. It is classified as family owned and is currently operating.
When was Chiesi founded?
Chiesi was founded in 1935. It employs 251 to 500 people.
Where is Chiesi based?
Chiesi is headquartered in Manchester, United Kingdom, in the Europe region.
How does Chiesi make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are rare Disease Portfolio Revenue.
Does Chiesi have an API?
No public API is recorded for Chiesi.
What industry is Chiesi in?
Chiesi's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.